{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:52:29Z","timestamp":1792266749177,"version":"4.4.0"},"reference-count":147,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>In recent years, the rapid progress in oncology, immunology, and molecular biology has dramatically advanced cancer immunotherapy, particularly CAR-T cell therapy. This innovative approach involves engineering a patient\u2019s T cells to express receptors that specifically target tumor antigens, enhancing their ability to identify and eliminate cancer cells. However, the effectiveness of CAR-T therapy in solid tumors is often hampered by the challenging tumor microenvironment (TME). The complex TME includes dense stroma that obstructs T cell infiltration, abnormal blood vessel structures leading to hypoxia, and an acidic pH, all of which hinder CAR-T cell function. Additionally, the presence of immunosuppressive factors in the TME reduces the efficacy of CAR-T cells, making successful targeting of tumors more difficult. The safety of CAR-T therapy has gained interest, especially CAR-T therapy has shown considerable effectiveness in various cancers, with notable results in multiple myeloma and hepatocellular carcinoma, among others. Nonetheless, CAR-T cell therapy is associated with several adverse reactions primarily driven by heightened levels of proinflammatory cytokines. These reactions include cytokine release syndrome (CRS), neurotoxicity (CANS), and organ toxicity, often leading to serious complications. CRS, characterized by systemic inflammation due to cytokine release, can escalate to severe organ dysfunction. It typically occurs within the first week post-infusion, correlating with CAR-T cell expansion and often presents with fever and hypotension. Meanwhile, CANS encompasses neurological issues ranging from mild symptoms to severe seizures, possibly exacerbated by CRS. Organ toxicity can also arise from CAR-T therapy, with potential damage affecting the gastrointestinal tract, kidneys, liver, and lungs, often tied to shared antigens found in both tumor and healthy tissues. Moreover, long-term effects like cytokine-associated hematotoxicity (CAHT) and secondary malignancies represent significant concerns that could affect the patient\u2019s quality of life post-treatment. The long-term adverse effects and challenges in treating solid tumors underscore the need for ongoing research. Strategies to improve CAR-T cell efficacy, minimize adverse reactions, and enhance patient safety are critical. Future explorations could include designing CAR-T cells to better navigate the TME, identifying specific target antigen profiles to minimize off-target damage, and developing adjunct therapies to mitigate cytokine-related toxicity. Continued monitoring for long-term effects will also be paramount in improving patient outcomes and maintaining their quality of life. Overall, while CAR-T therapy holds great promise, it must be administered with careful consideration of potential side effects and rigorous management strategies to ensure patient safety and treatment efficacy.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1548979","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T01:32:26Z","timestamp":1740360746000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["In-depth analysis of the safety of CAR-T cell therapy for solid tumors"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiayi","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiexiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Bei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Size","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Sci (New York NY)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"280ps7","DOI":"10.1126\/scitranslmed.aaa3643","article-title":"Adoptive cellular therapy: a race to the finish line","volume":"7","author":"June","year":"2015","journal-title":"Sci Transl Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00749-6","article-title":"Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial","volume":"5","author":"Hegde","year":"2024","journal-title":"Nat Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.872756","article-title":"PD1 expression in EGFRvIII-directed CAR T cell infusion product for glioblastoma is associated with clinical response","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3892\/ol.2023.13867","article-title":"Combination of CAR\u2212T cell therapy and radiotherapy: Opportunities and challenges in solid tumors (Review)","volume":"26","author":"Zhong","year":"2023","journal-title":"Oncol Lett"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2024.2380894","article-title":"CAR-T cell technologies that interact with the tumour microenvironment in solid tumours","volume":"20","author":"Taylor","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"188701","DOI":"10.1016\/j.bbcan.2022.188701","article-title":"Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors","volume":"1877","author":"Akbari","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009510","article-title":"Microenvironmental alkalization promotes the therapeutic effects of MSLN-CAR-T cells","volume":"12","author":"Wu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02905","article-title":"Anti-cancer therapies employing IL-2 cytokine tumor targeting: contribution of innate, adaptive and immunosuppressive cells in the anti-tumor efficacy","volume":"9","author":"Mortara","year":"2018","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005433","article-title":"Selective targeting of GARP-LTGF\u03b2 axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8(+) T cell antitumor immunity","volume":"10","author":"Li","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3390\/cancers13030401","article-title":"TGF-\u03b2 in cancer: metabolic driver of the tolerogenic crosstalk in the tumor microenvironment","volume":"13","author":"Angioni","year":"2021","journal-title":"Cancers"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI155621","article-title":"An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma","volume":"132","author":"Tian","year":"2022","journal-title":"J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1038\/s41467-023-37646-y","article-title":"Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models","volume":"14","author":"Yang","year":"2023","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113220","article-title":"Low dose of human scFv-derived BCMA-targeted CAR-T cells achieved fast response and high complete remission in patients with relapsed\/refractory multiple myeloma","volume":"132","author":"Jiang","year":"2018","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"New Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-CT031","article-title":"Abstract CT031: GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas","volume":"81","author":"Majzner","year":"2021","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221988","article-title":"Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy","volume":"221","author":"Lin","year":"2024","journal-title":"J Exp Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-802413","article-title":"Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights","volume":"130","author":"Obstfeld","year":"2017","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/his.14591","article-title":"Pathology updates and diagnostic approaches to haemophagocytic lymphohistiocytosis","volume":"80","author":"Kikuchi","year":"2022","journal-title":"Histopathology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001249","article-title":"Biomarkers for predicting cytokine release syndrome following CD19-targeted CAR T cell therapy","volume":"206","author":"Tedesco","year":"2021","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine release syndrome: current perspectives","volume":"8","author":"Murthy","year":"2019","journal-title":"Immunotargets Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s40425-019-0767-x","article-title":"Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy","volume":"7","author":"Luo","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663201","article-title":"Reactions related to CAR-T cell therapy","volume":"12","author":"Miao","year":"2021","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.AC119.007558","article-title":"Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators","volume":"294","author":"Sachdeva","year":"2019","journal-title":"J Biol Chem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000515","article-title":"Cytokine release syndrome biology and management","volume":"27","author":"Cobb","year":"2021","journal-title":"Cancer J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1158\/1078-0432.CCR-18-1379","article-title":"Plasma exchange can be an alternative therapeutic modality for severe cytokine release syndrome after chimeric antigen receptor-T cell infusion: A case report","volume":"25","author":"Xiao","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T\u2009cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"150931","DOI":"10.1016\/j.soncn.2019.08.010","article-title":"Management principles associated with cytokine release syndrome","volume":"35","author":"Baer","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2021.0057","article-title":"Prognostic significance of cytokine release syndrome in B cell hematological Malignancies patients after chimeric antigen receptor T cell therapy","volume":"41","author":"Dong","year":"2021","journal-title":"J Interferon Cytokine Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e57298","DOI":"10.7759\/cureus.57298","article-title":"An early neurological indicator of immune effector cell-associated neurotoxicity syndrome","volume":"16","author":"Yorichika","year":"2024","journal-title":"Cureus"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2021.11.001","article-title":"Management of CAR T-cell Related Toxicities: What did the Learning Curve Teach us so Far","volume":"15","author":"Murthy","year":"2022","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2024.04.014","article-title":"EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome","volume":"163","author":"Hernani","year":"2024","journal-title":"Clin Neurophysiol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3390\/biom13020382","article-title":"Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome","volume":"13","author":"Lakomy","year":"2023","journal-title":"Biomolecules"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e05209","DOI":"10.1002\/ccr3.v10.1","article-title":"Hemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS) following treatment with tisagenlecleucel","volume":"10","author":"Mart\u00edn-Rojas","year":"2022","journal-title":"Clin Case Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2023.06.008","article-title":"A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy","volume":"25","author":"Zu","year":"2023","journal-title":"Cytotherapy"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.745320","article-title":"Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-hodgkin lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221104816","article-title":"Use of long-term corticosteroids in patients treated with CAR T-cell therapy","volume":"29","author":"Hashmi","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2340738","article-title":"Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy","volume":"25","author":"Walton","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1881507","article-title":"Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature","volume":"62","author":"Major","year":"2021","journal-title":"Leukemi Lymphoma"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013688","article-title":"Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis","volume":"9","author":"Bajwa","year":"2025","journal-title":"Blood Adv"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8057","article-title":"Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel)","volume":"38","author":"Ahmed","year":"2020","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16176","article-title":"Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy","volume":"25","author":"Pan","year":"2021","journal-title":"J Cell Mol Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000002856","article-title":"Combined use of emapalumab with ruxolitinib and dexamethasone as an effective treatment for epstein-barr virus-associated hemophagocytic lymphohistiocytosis complicated with multiorgan damage and severe infection","volume":"46","author":"Liang","year":"2024","journal-title":"J Pediatr Hematology\/oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/jcm11010172","article-title":"Continuous renal replacement therapy in the critically ill patient: from garage technology to artificial intelligence","volume":"11","author":"Samoni","year":"2021","journal-title":"J Clin Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2020.02.010","article-title":"Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome","volume":"57","author":"Stahl","year":"2020","journal-title":"J Crit Care"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.14182","article-title":"Treatment of acute kidney injury with continuous renal replacement therapy and cytokine adsorber (CytoSorb\u00ae) in critically ill patients with COVID-19","volume":"28","author":"Jakopin","year":"2024","journal-title":"Ther Apheresis Dialysis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","article-title":"Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy","volume":"9","author":"Hu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-023-01315-w","article-title":"Neurotoxicity of cancer immunotherapies including CAR T cell therapy","volume":"23","author":"Song","year":"2023","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1272291","DOI":"10.3389\/fmed.2023.1272291","article-title":"Blood-brain barrier breakdown, central nervous system cell damage, and infiltrated T cells as major adverse effects in CAR-T-related deaths: a literature review","volume":"10","author":"Del Duca","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.877477","article-title":"EASIX and severe endothelial complications after CD19-directed CAR-T cell therapy-A cohort study","volume":"13","author":"Korell","year":"2022","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005459","article-title":"Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy","volume":"10","author":"Amidi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009525","article-title":"Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy","volume":"12","author":"Larue","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplantation"},{"key":"B64","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41421-021-00299-6","article-title":"Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic Malignancy","volume":"7","author":"Xue","year":"2021","journal-title":"Cell Discov"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00060-0","article-title":"Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study","volume":"8","author":"Azoulay","year":"2021","journal-title":"Lancet Haematol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03613-7","article-title":"Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients","volume":"147","author":"Zhang","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e1154","DOI":"10.1002\/cti2.v9.10","article-title":"Severe delayed pulmonary toxicity following PD-L1-specific CAR-T cell therapy for non-small cell lung cancer","volume":"9","author":"Liu","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.669071","article-title":"Case report: prolonged survival following EGFRvIII CAR T cell treatment for recurrent glioblastoma","volume":"11","author":"Durgin","year":"2021","journal-title":"Front Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-016-5024-7","article-title":"Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells","volume":"59","author":"You","year":"2016","journal-title":"Sci China Life Sci"},{"key":"B72","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol Ther"},{"key":"B74","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1186\/1471-2407-12-615","article-title":"Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive Malignant pleural mesothelioma (FAPME-1)","volume":"12","author":"Petrausch","year":"2012","journal-title":"BMC Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950923","article-title":"The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab4082","article-title":"Somatic mutation in cancer and normal cells","volume":"349","author":"Martincorena","year":"2015","journal-title":"Sci (New York NY)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy","volume":"78","author":"Goldman","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ Liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-hodgkin lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B82","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B84","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-016-5023-8","article-title":"Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed\/refractory non-small cell lung cancer","volume":"59","author":"Feng","year":"2016","journal-title":"Sci China Life Sci"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs140","article-title":"Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma","volume":"104","author":"Moldenhauer","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"20200663","DOI":"10.1259\/bjr.20200663","article-title":"Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography","volume":"94","author":"Anderson","year":"2021","journal-title":"Br J Radiol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with Malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discovery"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol Ther"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30172-3","article-title":"Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy","volume":"6","author":"Rashdan","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000260","article-title":"Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma","volume":"42","author":"Goff","year":"2019","journal-title":"J Immunother"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.36141\/svdld.v33i2.5030","article-title":"High-resolution CT predictors of hypersensitivity pneumonitis","volume":"33","author":"Rival","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.159.3.1503007","article-title":"Hypersensitivity pneumonitis: sensitivity of high-resolution CT in a population-based study","volume":"159","author":"Lynch","year":"1992","journal-title":"AJR Am J Roentgenol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1505197","article-title":"Anti-PD-1-related pneumonitis during cancer immunotherapy","volume":"373","author":"Nishino","year":"2015","journal-title":"New Engl J Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00344-7","article-title":"Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues","volume":"3","author":"Feng","year":"2022","journal-title":"Nat Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2022.05.018","article-title":"Incidence and risk factors for acute kidney injury after chimeric antigen receptor T-cell therapy","volume":"97","author":"Farooqui","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.06.024","article-title":"Dermatologic adverse events associated with chimeric antigen receptor T-cell therapy: A pharmacovigilance analysis of the FDA reporting system","author":"Storgard","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0432","article-title":"Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers","volume":"24","author":"Guo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.04.088","article-title":"Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial","volume":"22","author":"Liu","year":"2020","journal-title":"Cytotherapy"},{"key":"B102","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-016-0378-7","article-title":"Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma","volume":"10","author":"Feng","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011767","article-title":"Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality","volume":"8","author":"Rejeski","year":"2024","journal-title":"Blood Adv"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000845","article-title":"41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo","volume":"8","author":"Baroni","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.798352","article-title":"Case report: sirolimus alleviates persistent cytopenia after CD19 CAR-T-cell therapy","volume":"11","author":"Xing","year":"2021","journal-title":"Front Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002721","article-title":"Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report","volume":"9","author":"Baur","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06704-2","article-title":"Latent human herpesvirus 6 is reactivated in CAR T cells","volume":"623","author":"Lareau","year":"2023","journal-title":"Nature"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological Malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S280535","article-title":"Sustained remission of relapsed or refractory mantle cell lymphoma after 4-1BB-based CD19-directed CAR-T therapy","volume":"13","author":"Yang","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.254045","article-title":"Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma","volume":"106","author":"Strati","year":"2021","journal-title":"Haematologica"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell Malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"B119","doi-asserted-by":"publisher","first-page":"ofae422","DOI":"10.1093\/ofid\/ofae422","article-title":"Cytomegaloviral infections in recipients of chimeric antigen receptor T-cell therapy: an observational study with focus on oncologic outcomes","volume":"11","author":"Khawaja","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"B120","doi-asserted-by":"publisher","first-page":"2381989","DOI":"10.1080\/16078454.2024.2381989","article-title":"Procalcitonin level threshold and antibiotic use in patients receiving chimeric antigen receptor T-cell therapy","volume":"29","author":"Ramesh","year":"2024","journal-title":"Hematology"},{"key":"B121","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","article-title":"Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia","volume":"16","author":"Tan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3322\/caac.21702","article-title":"Critical care management of chimeric antigen receptor T-cell therapy recipients","volume":"72","author":"Shimabukuro-Vornhagen","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"New Engl J Med"},{"key":"B124","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1182\/blood-2023-179480","article-title":"Single-Cell Multi-Omics Reveals Type-2 Functionality in Maintaining CAR T Cell Longevity Associated with 8-Year Leukemia Remission","volume":"142","author":"Bai","year":"2023","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3390\/cancers14041078","article-title":"Knowns and unknowns about CAR-T cell dysfunction","volume":"14","author":"Titov","year":"2022","journal-title":"Cancers"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J Clin Invest"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.12.004","article-title":"A metabolic switch to memory CAR T cells: Implications for cancer treatment","volume":"500","author":"Rostamian","year":"2021","journal-title":"Cancer Lett"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03237","article-title":"Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.731435","article-title":"Chimeric antigens receptor T cell therapy improve the prognosis of pediatric acute lymphoblastic leukemia with persistent\/recurrent minimal residual disease in first complete remission","volume":"12","author":"Hu","year":"2021","journal-title":"Front Immunol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.3390\/ijms24065688","article-title":"CAR T-cell persistence correlates with improved outcome in patients with B-cell lymphoma","volume":"24","author":"Wittibschlager","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B135","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/blood.2022015728","article-title":"Long-term follow-up for the development of subsequent Malignancies in patients treated with genetically modified IECs","volume":"140","author":"Steffin","year":"2022","journal-title":"Blood"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Sci (New York NY)"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J Clin Invest"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.08.006","article-title":"Screening clinical cell products for replication competent retrovirus: the national gene vector biorepository experience","volume":"10","author":"Cornetta","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000219","article-title":"Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy","volume":"3","author":"Shah","year":"2019","journal-title":"Blood Adv"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03478-6","article-title":"Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies","author":"Jadlowsky","year":"2025","journal-title":"Nat Med"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.v203.5","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(23)02747-2","article-title":"FDA investigating safety risks in CAR T-cell recipients","volume":"402","author":"Nelson","year":"2023","journal-title":"Lancet (London England)"},{"key":"B144","doi-asserted-by":"publisher","first-page":"17588359241266140","DOI":"10.1177\/17588359241266140","article-title":"Strategies to overcome tumor microenvironment immunosuppressive effect on the functioning of CAR-T cells in high-grade glioma","volume":"16","author":"Zarychta","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02661-1","article-title":"Augmenting engineered T-cell strategies in solid cancers through epigenetic priming","volume":"69","author":"Nielsen","year":"2020","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B146","doi-asserted-by":"publisher","first-page":"e70283","DOI":"10.1002\/cam4.v13.19","article-title":"Unlocking apoptotic pathways: overcoming tumor resistance in CAR-T-cell therapy","volume":"13","author":"Zhang","year":"2024","journal-title":"Cancer Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1389971","article-title":"The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review","volume":"15","author":"Satapathy","year":"2024","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1548979\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T01:32:33Z","timestamp":1740360753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1548979\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":147,"alternative-id":["10.3389\/fimmu.2025.1548979"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1548979","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"article-number":"1548979"}}